Abstract
20%-25% (28%-35%); High blast count; Poor prognosisespecially in cases with high mutant to WT allelic ratio5%-7% (10%-14%); Prognostic impact remains controversial10% (9%-14%); Enriched in CBF AML; Prognosis unknown<5% (<5%); 25-30% in CBF leukaemia<2% (2%); Prognosis unknown25%-30% (40%-65%); M4 blast morphology lacks CD34 expression; Hox gene upregulation; Favorable prognosis inthe presence of
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
